COMPANY PROFILE

M2Gen

Explore full profile

A health informatics solutions company - aiming to improve cancer care by accelerating precision medicine

Tampa, United StatesFounded 2006Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About M2Gen

M2GEN is an oncology-focused health informatics solutions company dedicated to transforming cancer care. The company leverages clinical and molecular data to accelerate the discovery, development, and delivery of personalized therapies. M2GEN partners with 18 leading cancer centers through the Oncology Research Information Exchange Network (ORIEN) to provide innovative solutions that enhance precision medicine. By analyzing patient-derived tumor specimens and translating new molecular observations, M2GEN connects patients, providers, and researchers to fundamentally change the way cancer is studied and treated. The company serves healthcare providers, researchers, and patients, operating in the oncology and precision medicine market. M2GEN's business model revolves around providing data-driven insights and solutions that facilitate the development of tailored cancer treatments. Revenue is generated through partnerships, data services, and collaborative research initiatives.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: Tampa, United States
Employees: 37
Open positions: None listed
Dealroom signal: 62.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Mar 2021	$100M	$400M	CD&R · Merck Global Health Innovation Fund · McKesson Ventures	—
LATE VCOther financing	Sep 2017	$75M	$300M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

M2Gen website traffic

Latest recorded traffic for M2Gen is 2.7K monthly website visits, down 63% over the last three months. M2Gen's team declined 7.5% over the past year.

Latest monthly visits2.7K 3-month web change-63% 1-year team growth-7.5%

Monthly website visitsOct 2017–Apr 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational	15	$25M	$100M
CTCelsius TherapeuticsSingle-cell RNA sequencing and genomic analysis	Cambridge, United States	Acquired
ATAbdera TherapeuticsUses antibody engineering to design and develop new precision radiotherapeutics for cancer	South San Francisco, United States	Operational
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational
STSoley TherapeuticsDrug discovery and development company using cellular responses and AI to identify novel therapies for complex diseases	Brentwood, United States	Operational
NUNuvalentTargeted small-molecule cancer therapies for kinase-driven cancers	Cambridge, United States	Acquired
ATAi TherapeuticsAI Therapeutics - Deep Learning Precision Medicine	Guilford, United States	Acquired
QUQualisuredxDeveloping molecular tests that enhance cancer care by identifying features that help oncologists to personalize treatments	Calgary, Canada	Operational